The Advisory Committee of the Swedish MPA recommends RescueFlow for approval

The Advisory Committee of the Swedish Medical Products Agency recommends RescueFlow® for approval. The Advisory Committee of the MPA has, with an addition to the product information, recommended the approval of BioPhausia´s product RescueFlow® for marketing in Sweden. RescueFlow® is intended for initial treatment of hypotension due to traumatic injury. BioPhausia will use the mutual recognition procedure for registration in the other EU countries. These countries are expected to approve the product, based on MPA´s approval and assessment, during the first half of 1999. Company President Stellan Lind comments: "It is a great achievement for us that the Advisory Panel has recommended approval of RescueFlow®. We now belong to the group of R&D companies that has taken a product to regulatory approval. Negotiations about licensing of the marketing rights to RescueFlow® are under way." Uppsala, November 15, 1998. Based on its contact network and know-how, primarily in connective tissue biology, BioPhausia is developing products for licensing to well-established pharmaceutical companies with strong marketing organizations. The project portfolio includes RescueFlow®, a resuscitation solution (registration phase), Krillase® for the debridement of chronic wounds (clinical phase III), and preclinical projects in the tumor and trauma treatment areas. For further information, please contact: Stellan Lind, President Tel. +46 (0)18-34 99 00 ------------------------------------------------------------ Please visit http://www.bit.se for further information The following files are available for download: http://www.bit.se/bitonline/1998/11/16/19981116BIT00110/bit0001.pdf http://www.bit.se/bitonline/1998/11/16/19981116BIT00110/bit0002.doc